The BCD-100-3/DOMAJOR clinical study evaluates the efficacy and safety of BCD-100 in combination with chemotherapy versus first-line chemotherapy in patients with advanced non-small cell lung cancer who:
Are diagnosed with "metastatic non-squamous NSCLC" (stage IV, M1a/M1b/M1c, according to the 8th edition of the AJCC staging system), which is histologically confirmed and not treated previously.
Are aged 18 years or older.
The BCD-100-3/DOMAJOR study takes place at 51 study centers in Moscow, Saint Petersburg, and other cities in the Russian Federation.
Participation of a maximum of 176 people in the Russian Federation has been approved for this study.
This study is also conducted in the PRC and European Union member states.
Authorization of the Ministry of Health of the Russian Federation for this clinical study, No. 406 dated August 09, 2018, and the list of approved study centers have been published in the State Register of Medicines.